title: ApoA-II maintains HDL levels in part by inhibition of hepatic lipase. Studies In apoA-II and hepatic lipase double knockout mice.
abstract: High density lipoprotein (HDL) cholesterol levels are inversely related to the risk of developing coronary heart disease. Apolipoprotein (apo) A-II is the second most abundant HDL apolipoprotein and apoA-II knockout mice show a 70% reduction in HDL cholesterol levels. There is also evidence, using human apoA-II transgenic mice, that apoA-II can prevent hepatic lipase-mediated HDL triglyceride hydrolysis and reduction in HDL size. These observations suggest the hypothesis that apoA-II maintains HDL levels, at least in part, by inhibiting hepatic lipase. To evaluate this, apoA-II knockout mice were crossbred with hepatic lipase knockout mice. Compared to apoA-II-deficient mice, in double knockout mice there were increased HDL cholesterol levels (57% in males and 60% in females), increased HDL size, and decreased HDL cholesteryl ester fractional catabolic rate. In vitro incubation studies of plasma from apoA-II knockout mice, which contains largely apoA-I HDL particles, showed active lipolysis of HDL triglyceride, whereas similar studies of plasma from apoA-I knockout mice, which contains largely apoA-II particles, did not. In summary, these results strongly suggest that apoA-II is a physiological inhibitor of hepatic lipase and that this is at least part of the mechanism whereby apoA-II maintains HDL cholesterol levels.
authors.affiliation: Laboratory of Biochemical Genetics and Metabolism, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA.
authors.forename: W
authors.initials: W
authors.lastname: Weng
authors.forename: N A
authors.initials: NA
authors.lastname: Brandenburg
authors.forename: S
authors.initials: S
authors.lastname: Zhong
authors.forename: J
authors.initials: J
authors.lastname: Halkias
authors.forename: L
authors.initials: L
authors.lastname: Wu
authors.forename: X C
authors.initials: XC
authors.lastname: Jiang
authors.forename: A
authors.initials: A
authors.lastname: Tall
authors.forename: J L
authors.initials: JL
authors.lastname: Breslow
mesh_terms: D000818:Animals; D016633:Apolipoprotein A-II / Q000172:deficiency / Q000235:genetics* / Q000494:pharmacology*; D002788:Cholesterol Esters / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003433:Crosses, Genetic; D005260:Female; D006801:Humans; D006868:Hydrolysis; D008049:Lipase / Q000037:antagonists & inhibitors* / Q000172:deficiency / Q000235:genetics*; D008066:Lipolysis; D008075:Lipoproteins, HDL / Q000097:blood*; D008099:Liver / Q000201:enzymology*; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D010316:Particle Size; D014280:Triglycerides / Q000097:blood
chemical_list: D016633:Apolipoprotein A-II; D002788:Cholesterol Esters; D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D014280:Triglycerides; D008049:Lipase